UTHR — United Therapeutics Corporation
Is UTHR overbought or oversold? Here is the current MarketMoodz read.
United Therapeutics Corporation (UTHR) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $584.10. The rating moved from Overbought to Neutral on November 16, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$584.10
- Last changeMoved from Overbought to Neutral on November 16, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
AI analysis
United Therapeutics Corporation (UTHR) combines a steady, high‑margin PAH commercial business with optionality from advanced organ‑manufacturing and specialty biologics programs. Financially, the company has historically generated meaningful cash flow that supports R&D and strategic investments, while its product concentration provides pricing power in a niche market. Near‑term market conditions are calm and healthcare interest is selective, which should limit headline‑driven volatility. Key catalysts include pipeline readouts, regulatory milestones, and continued commercialization performance; adverse reimbursement moves, clinical setbacks, or manufacturing scale issues represent the primary downside scenarios.
Key factors
- Established commercial franchise in pulmonary arterial hypertension with stable, recurring revenue streams from inhaled and parenteral therapies
- Strong cash flow generation and historically solid balance sheet enabling continued R&D and strategic investments in organ manufacturing and specialty products
- Differentiated technical capabilities in biologics manufacturing and novel organ-replacement research that provide long-term optionality beyond core PAH drugs
- Limited recent headline risk in filings (neutral SEC filing) and a broadly steady market environment reducing near-term volatility
- Selective investor interest in healthcare and specialty pharma niches supports defensive positioning relative to broader growth volatility
- Concentration in a specialized therapeutic area with high pricing power versus broader exposure, reducing sensitivity to cyclical swings in general markets
Risks
- Regulatory and reimbursement pressure — broader Medicare/Medicaid program integrity actions and payer scrutiny could reduce net pricing or increase administrative costs
- Clinical and regulatory execution risk for pipeline and organ‑manufacturing programs; failed trials or delays would materially impact valuation
- Competitive threats from new therapies or delivery modalities in pulmonary hypertension that could erode market share over time
- Manufacturing and scale-up risks, particularly for advanced biologics and organ platforms that require complex, capital‑intensive infrastructure
- High valuation and investor concentration in specialty biotech — sensitive to broader sentiment shifts and quarterly earnings surprises
- Single‑disease concentration risk: dependence on PAH markets exposes revenue to demand shocks or changes in prescribing patterns
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for UTHR — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.